Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis

References

• KernanWNOvbiageleBBlackHRGuidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke AssociationStroke2014457 2160 223624788967
   PubMed Web of Science ®Google Scholar
• FinkelJBDuffyD2013 ACC/AHA cholesterol treatment guideline: paradigm shifts in managing atherosclerotic cardiovascular disease riskTrends Cardiovasc Med2015254 340 34725435519
   PubMed Web of Science ®Google Scholar
• AmarencoPLabreucheJLipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke preventionLancet Neurol200985 453 46319375663
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation (ESO) Executive CommitteeESO Writing CommitteeGuidelines for management of ischaemic stroke and transient ischaemic attack 2008Cerebrovasc Dis2008255 457 50718477843
   PubMed Web of Science ®Google Scholar
• Chinese Society of Neurology, Neurology Cerebrovascular Group2014 Guideline of the secondary prevention of ischemic stroke and transient ischemic attack in ChinaChin J Neurol2015484 258 273
   Google Scholar
• CannonCPSteinbergBAMurphySAMegaJLBraunwaldEMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapyJ Am Coll Cardiol2006483 438 44516875966
   PubMed Web of Science ®Google Scholar
• ZhouZRahmeEPiloteLAre statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease preventionAm Heart J20061512 273 28116442888
   PubMed Web of Science ®Google Scholar
• NaciHBrugtsJJFleurenceRAdesAEComparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trialsQJM20131064 299 30623431221
   PubMed Web of Science ®Google Scholar
• AlbertonMWuPDruytsEBrielMMillsEJAdverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysisQJM20121052 145 15721920996
   PubMed Web of Science ®Google Scholar
• MillsEJRachlisBWuPDevereauxPJAroraPPerriDPrimary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patientsJ Am Coll Cardiol20085222 1769 178119022156
   PubMed Web of Science ®Google Scholar
• MillsEJWuPChongGEfficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trialsQJM20111042 109 12420934984
   PubMed Web of Science ®Google Scholar
• RibeiroRAZiegelmannPKDuncanBBImpact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patientsInt J Cardiol20131662 431 43922192281
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med199833919 1349 13579841303
   PubMed Web of Science ®Google Scholar
• Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico)Ital Heart J2000112 810 82011302109
   PubMedGoogle Scholar
• BertrandMEMcFaddenEPFruchartJCEffect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by elisor after transluminal coronary angioplastyJ Am Coll Cardiol1997304 863 8699316510
   PubMed Web of Science ®Google Scholar
• CrouseJR3rdByingtonRPBondMGPravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)Am J Cardiol1995757 455 4597863988
   PubMed Web of Science ®Google Scholar
• JukemaJWBruschkeAVvan BovenAJEffects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)Circulation19959110 2528 25407743614
   PubMed Web of Science ®Google Scholar
• MakuuchiHFuruseAEndoMEffect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgeryCirc J2005696 636 64315914938
   PubMed Web of Science ®Google Scholar
• NakagawaTKobayashiTAwataNRandomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) studyInt J Cardiol2004971 107 11415336816
   PubMed Web of Science ®Google Scholar
• PittBManciniGBEllisSGRosmanHSParkJSMcGovernMEPravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigationJ Am Coll Cardiol1995265 1133 11397594023
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsN Engl J Med199633514 1001 10098801446
   PubMed Web of Science ®Google Scholar
• SatoHKinjoKItoHEffect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID StudyCirc J2008721 17 2218159093
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet20023609346 1623 163012457784
   PubMed Web of Science ®Google Scholar
• ThompsonPLMeredithIAmerenaJCampbellTJSlomanJGHarrisPJEffect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trialAm Heart J20041481 e215215811
   PubMed Web of Science ®Google Scholar
• YokoiHNobuyoshiMMitsudoKKawaguchiAYamamotoAATHEROMA Study InvestigatorsThree-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) studyCirc J2005698 875 88316041153
   PubMed Web of Science ®Google Scholar
• AmarencoPBogousslavskyJCallahanA3rdHigh-dose atorvastatin after stroke or transient ischemic attackN Engl J Med20063556 549 55916899775
   PubMed Web of Science ®Google Scholar
• AthyrosVGKakafikaAIPapageorgiouAAEffects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE StudyCurr Med Res Opin2008246 1593 159918430270
   PubMed Web of Science ®Google Scholar
• BaeJHBassengeEKimKYSynnYCParkKRSchwemmerMEffects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stentingJ Cardiovasc Pharmacol Ther200493 185 19215378139
   PubMed Web of Science ®Google Scholar
• KnoppRHd’EmdenMSmildeJGPocockSJEfficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)Diabetes Care2006297 1478 148516801565
   PubMed Web of Science ®Google Scholar
• KorenMJHunninghakeDBClinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance studyJ Am Coll Cardiol2004449 1772 177915519006
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGEzekowitzMDEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trialJAMA200128513 1711 171811277825
   PubMed Web of Science ®Google Scholar
• StonePHLloyd-JonesDMKinlaySEffect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the vascular basis for the treatment of Myocardial Ischemia StudyCirculation200511114 1747 175515809368
   PubMed Web of Science ®Google Scholar
• BlankenhornDHAzenSPKramschDMCoronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)Ann Intern Med199311910 969 9768214993
   PubMed Web of Science ®Google Scholar
• WatersDHigginsonLGladstonePEffects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention TrialCirculation1994893 959 9688124836
   PubMed Web of Science ®Google Scholar
• WeintraubWSBoccuzziSJKleinJLLack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study GroupN Engl J Med199433120 1331 13377935702
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934 1383 13897968073
   PubMed Web of Science ®Google Scholar
• Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)Lancet19943448923 633 6387864934
   PubMed Web of Science ®Google Scholar
• TeoKKBurtonJRBullerCELong-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)Circulation200010215 1748 175411023927
   PubMed Web of Science ®Google Scholar
• LiemAHvan BovenAJVeegerNJEffect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trialEur Heart J20022324 1931 193712473255
   PubMed Web of Science ®Google Scholar
• OstadalPAlanDVejvodaJFluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)Trials201011 6120500832
   PubMed Web of Science ®Google Scholar
• SerruysPWde FeyterPMacayaCFluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trialJAMA200228724 3215 322212076217
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVRosuvastatin in older patients with systolic heart failureN Engl J Med200735722 2248 226117984166
   PubMed Web of Science ®Google Scholar
• TavazziLMaggioniAPMarchioliREffect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialLancet20083729645 1231 123918757089
   PubMed Web of Science ®Google Scholar
• TakanoHMizumaHKuwabaraYEffects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study)Circ J2013774 917 92523502990
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med200435015 1495 150415007110
   PubMed Web of Science ®Google Scholar
• DeedwaniaPStonePHBairey MerzCNEffects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)Circulation20071156 700 70717283260
   PubMed Web of Science ®Google Scholar
• HallASJacksonBMFarrinAJA randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets TrialEur J Cardiovasc Prev Rehabil2009166 712 72119745745
   PubMedGoogle Scholar
• IzawaAKashimaYMiuraTAssessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI studyCirc J2015791 161 16825392071
   PubMed Web of Science ®Google Scholar
• LablancheJMLeoneAMerkelyBComparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS studyArch Cardiovasc Dis20101033 160 16920417447
   PubMed Web of Science ®Google Scholar
• NichollsSJBallantyneCMBarterPJEffect of two intensive statin regimens on progression of coronary diseaseN Engl J Med201136522 2078 208722085316
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA20042919 1071 108014996776
   PubMed Web of Science ®Google Scholar
• OlssonAGErikssonMJohnsonOA 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) studyClin Ther2003251 119 13812637115
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA200529419 2437 244516287954
   PubMed Web of Science ®Google Scholar
• PittBLoscalzoJMonyakJMillerERaichlenJComparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study)Am J Cardiol20121099 1239 124622360820
   PubMed Web of Science ®Google Scholar
• Amin-HanjaniSStaglianoNEYamadaMHuangPLLiaoJKMoskowitzMAMevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in miceStroke2001324 980 98611283400
   PubMed Web of Science ®Google Scholar
• AsahiMHuangZThomasSProtective effects of statins involving both eNOS and tPA in focal cerebral ischemiaJ Cereb Blood Flow Metab2005256 722 72915716855
   PubMed Web of Science ®Google Scholar
• ChenJZhangZGLiYStatins induce angiogenesis, neurogenesis, and synaptogenesis after strokeAnn Neurol2003536 743 75112783420
   PubMed Web of Science ®Google Scholar
• Di NapoliPTaccardiAAOliverMDe CaterinaRStatins and stroke: evidence for cholesterol-independent effectsEur Heart J20022324 1908 192112473253
   PubMed Web of Science ®Google Scholar
• EndresMLaufsUHuangZStroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthaseProc Natl Acad Sci U S A19989515 8880 88859671773
   PubMed Web of Science ®Google Scholar
• KawashimaSYamashitaTMiwaYHMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive ratsStroke2003341 157 16312511768
   PubMed Web of Science ®Google Scholar
• SironiLCiminoMGuerriniUTreatment with statins after induction of focal ischemia in rats reduces the extent of brain damageArterioscler Thromb Vasc Biol2003232 322 32712588778
   PubMed Web of Science ®Google Scholar
• VaughanCJDelantyNNeuroprotective properties of statins in cerebral ischemia and strokeStroke1999309 1969 197310471452
   PubMed Web of Science ®Google Scholar
• ElkindMSFlintACSciaccaRRSaccoRLLipid-lowering agent use at ischemic stroke onset is associated with decreased mortalityNeurology2005652 253 25816043795
   PubMed Web of Science ®Google Scholar
• HassanYAl-JabiSWAzizNALooiIZyoudSHStatin use prior to ischemic stroke onset is associated with decreased in-hospital mortalityFundam Clin Pharmacol2011253 388 39420608996
   PubMed Web of Science ®Google Scholar
• Marti-FabregasJGomisMArboixAFavorable outcome of ischemic stroke in patients pretreated with statinsStroke2004355 1117 112115073403
   PubMed Web of Science ®Google Scholar
• SaccoRLAdamsRAlbersGGuidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guidelineCirculation200611310 e409 e44916534023
   PubMed Web of Science ®Google Scholar
• Huwiler-MuntenerKJuniPJunkerCEggerMQuality of reporting of randomized trials as a measure of methodologic qualityJAMA200228721 2801 280412038917
   PubMed Web of Science ®Google Scholar